Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
34 studies found for:    BIBF 1120 | Phase 2
Show Display Options
Rank Status Study
1 Completed
Has Results
BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer
Condition: Colorectal Neoplasms
Interventions: Drug: BIBF 1120;   Drug: mFolfox;   Drug: Bevacizumab;   Drug: mFolfox 6;   Drug: bevacizumab
2 Completed
Has Results
Safety and PK Study of BIBF 1120 in Japanese Patients With IPF
Condition: Idiopathic Pulmonary Fibrosis
Interventions: Drug: Placebo;   Drug: BIBF 1120
3 Active, not recruiting Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib.
Condition: Carcinoma, Renal Cell
Interventions: Drug: BIBF 1120;   Drug: sunitinib
4 Active, not recruiting Roll Over Study From 1199.30 BIBF 1120 in Idiopathic Pulmonary Fibrosis (IPF)
Condition: Pulmonary Fibrosis
Intervention: Drug: BIBF 1120
5 Recruiting NOA-12: BIBF1120 and R-RT in Glioblastoma
Condition: Glioblastoma Multiforme
Interventions: Drug: BIBF 1120;   Radiation: radiotherapy
6 Completed
Has Results
Safety And Efficacy of BIBF 1120 in Idiopathic Pulmonary Fibrosis
Condition: Pulmonary Fibrosis
Interventions: Drug: low dose BIBF1120 once daily;   Drug: low dose BIBF 1120 twice daily;   Drug: intermediate dose BIBF 1120 twice daily;   Drug: high dose BIBF 1120 twice daily;   Drug: placebo
7 Recruiting BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
Intervention: Drug: BIBF 1120
8 Recruiting Low Dose Cyclophosphamide +/-- Nintedanib in Advanced Ovarian Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Cancer
Intervention: Drug: BIBF 1120
9 Completed
Has Results
A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate Cancer
Condition: Prostatic Neoplasms
Interventions: Drug: BIBF 1120;   Drug: BIBW 2992;   Drug: Sequential BIBF 1120 + BIBW 2992
10 Unknown  BIBF 1120 as Second Line Treatment for Small Cell Lung Cancer
Conditions: Small Cell Lung Cancer;   Small Cell Lung Cancer Recurrent
Intervention: Drug: BIBF 1120
11 Not yet recruiting A Study to Evaluate the Good and Bad Effects of BIBF1120 in Small Cell Lung Cancer Patients Who Have Previously Benefited From First-line Platinum-based Chemotherapy
Conditions: Small Cell Lung Cancer;   Platinum-sensitive
Intervention: Drug: BIBF1120
12 Terminated Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: Doxil (Pegylated Liposomal Doxorubicin);   Drug: BIBF 1120
13 Not yet recruiting BIBF1120 in Patients With Advanced FGFR3 Mutated,Overexpressed,or Wild Type Urothelial Carcinoma
Condition: Urothelial Carcinoma
Intervention: Drug: BIBF1120
14 Completed Efficacy and Safety of Oral Treatment With BIBF 1120 ES in Advanced Non-small-cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: BIBF 1120 ES low dose;   Drug: BIBF 1120 ES high dose;   Drug: Placebo to BIBF 1120 ES
15 Completed A Study With BIBF 1120 in Patients With Hormone Refractory Prostate Cancer
Condition: Prostatic Neoplasms
Interventions: Drug: BIBF 1120 low dose;   Drug: BIBF 1120 high dose
16 Active, not recruiting Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Interventions: Drug: Sorafenib;   Drug: BIBF 1120
17 Active, not recruiting Safety and PK Study of BIBF 1120 in Japanese Patients With IPF: Follow up Study From 1199.31(NCT01136174)
Condition: Pulmonary Fibrosis
Intervention: Drug: BIBF 1120
18 Active, not recruiting Neoadjuvant Paclitaxel Versus BIBF 1120 Priming Followed by BIBF 1120 Plus Paclitaxel in Early HER-2 Negative Breast Cancer With Proteomic and Dynamic Imaging Correlates
Condition: Breast Cancer
Interventions: Drug: BIBF + Paclitaxel;   Drug: Paclitaxel
19 Unknown  TRICC-C (AIO-KRK-0111): BIBF 1120 Versus Placebo in Patients Receiving Oxaliplatin Plus Fluorouracil and Leucovorin (mFOLFOX6) for Advanced, Chemorefractory Metastatic Colorectal Cancer (mCRC)
Condition: Colorectal Cancer
Interventions: Drug: mFOLFOX6 + BIBF 1120;   Drug: mFOLFOX6+placebo
20 Active, not recruiting Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
Conditions: Endometrial Adenocarcinoma;   Endometrial Adenosquamous Carcinoma;   Endometrial Clear Cell Adenocarcinoma;   Recurrent Uterine Corpus Carcinoma
Intervention: Drug: Nintedanib

   Previous Page Studies Shown (1-20) Next Page (21-34) Show next page of results    Last Page
Indicates status has not been verified in more than two years